Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...
Roche acquired rights to an obesity therapy by Danish biotech firm Zealand Pharma in a collaboration deal worth up to $5.3 ...
LoveRugbyLeague on MSN12d
The LRL Las Vegas Diary: Behind the scenes on game-day – and plans for 2026In the final part of his Las Vegas diary, Ross Heppenstall takes in Saturday’s four-game spectacular and saw Wigan Warriors ...
One of the world's most globally recognised liver cancer treatments will receive public funding from today. Tecentriq ...
New Zealanders now have funded access to a global standard of care treatment for a form of liver cancer, Hepatocellular Carcinoma (HCC), which, unlike many other cancers has a rapidly increasing rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback